Gastric adenocarcinoma (STAD) is a type of stomach cancer that accounts for 95% of gastric cancers and has poor survival rates. A recent study focused on a biological process called "lactylation," where lactate molecules attach to proteins, influencing metabolism and gene expression in cancer.
Gastric adenocarcinoma (STAD) is a type of stomach cancer that accounts for 95% of gastric cancers and has poor survival rates. A recent study focused on a biological process called "lactylation," where lactate molecules attach to proteins, influencing metabolism and gene expression in cancer. The study aimed to identify lactylation-related genes (LRGs) that could predict patient outcomes and immune system involvement in STAD.
Researchers analyzed data from 375 STAD samples and 32 normal tissues, identifying 12 key LRGs. They built a six-gene model (including DHRS7, NOP2, CRABP2, CALD1, ALB, and RIMS1) to predict patient survival. Patients with higher risk scores had shorter survival times. Among these genes, DHRS7 was studied in-depth.
DHRS7 levels were lower in cancer tissues but higher in advanced stages, correlating with worse outcomes. It was linked to immune cells like macrophages, particularly M2 macrophages, which promote an immunosuppressive tumor environment. DHRS7 also influenced key cancer pathways (e.g., PI3K-AKT and TGF-β) and processes like tumor growth, invasion, and immune escape.
Interestingly, DHRS7 acted as a tumor suppressor in early stages but promoted cancer in later stages, similar to other proteins like TGF-β. This dual role makes it a potential target for personalized therapies. The study suggests that lactylation-based gene signatures, especially DHRS7, could serve as biomarkers for prognosis and guide immunotherapy or metabolism-focused treatments in STAD. However, further research is needed to validate these findings and explore DHRS7's mechanisms.
Introduction: Intrahepatic cholangiocarcinoma (ICC) is an aggressive primary liver cancer with poor prognosis and limited treatment options. While ICC has traditionally been considered a malignancy of biliary epithelial cells, increasing evidence suggests that hepatocytes can...
Introduction: Liver fibrosis is the key determinant of long-term outcomes in metabolic dysfunction-associated steatohepatitis (MASH). Activated hepatic stellate cells (HSCs) drive fibrogenesis, but effective antifibrotic therapies remain unavailable. This study investigated whether blocking the succinate–GPR91...
Introduction: The progression from metabolic dysfunction-associated fatty liver (MAFL) to metabolic dysfunction-associated steatohepatitis (MASH) is driven by complex interactions between hepatocytes and immune cells. This study identifies a novel spatial mechanism in the periportal (PP)...
Introduction: Cardiovascular–Kidney–Metabolic (CKM) syndrome recognizes the close interaction between obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. This review highlights the emerging role of the gut microbiome, particularly butyrate-producing bacteria, as a central...
• Small intestinal adenocarcinoma (SIA) is a rare gastrointestinal cancer with limited disease-specific prognostic biomarkers and generally poor outcomes. • This nationwide Dutch population-based study evaluated whether three routinely available immunohistochemical markers—CK7, CK20, and CDX2—have...
Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) is closely linked to insulin resistance and type 2 diabetes, with the liver traditionally viewed as a key regulator of blood glucose through hepatic glucose production. However, emerging...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.